Treatment of relapsed multiple myeloma: Evidence-based recommendations

Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Samaras, Jason Valent, Chakra Chaulagain, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.

Original languageEnglish (US)
Article number100616
JournalBlood Reviews
StatePublished - Jan 2020


  • Evidence-based
  • Multiple myeloma
  • Refractory
  • Relapsed
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Treatment of relapsed multiple myeloma: Evidence-based recommendations'. Together they form a unique fingerprint.

Cite this